Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd has demonstrated significant advancements in its intellectual property portfolio and strong partnerships, particularly with AbbVie, which has already resulted in $24 million out of a potential $50 million in milestone payments, showcasing commercial viability and confidence in its rhCollagen technology. The recent patent, expiring in 2039, enhances CollPlant's competitive edge in the aesthetics market, further solidifying its long-term growth prospects in regenerative medicine. Additionally, strategic cost reduction initiatives are in place to extend the company's financial runway, positioning it favorably for upcoming human trials and future developments.

Bears say

CollPlant Biotechnologies Ltd operates within a highly specialized market focused on regenerative and aesthetic medicine, primarily relying on its rhCollagen products and BioInk for revenue generation. Despite its innovative technology, the company faces challenges with sales performance in its core markets, particularly in Europe for critical applications like tendinopathy and wound healing, which could undermine its financial stability. Additionally, the reliance on business collaborations for revenue may expose CollPlant to greater volatility and financial risk, further contributing to a negative outlook for its stock.

CLGN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 4 analysts, CLGN has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.